## Summary minutes of the 11th Institutional Review Board Meeting in FY2021 (Expedited review)

Date & time	Thursday, September 30, 2021, 10:00 - 11:00		
Place	(Hiroshima) Auditorium		
	(Nagasaki) The 3rd Conference Room [teleconference]		
Participants	IRB co-chairpersons: Dr. Tanabe, Ms. Shinohara		
	IRB members: Dr. Sato, Ms. Ogawa		

## < Review of research involving human subjects >

	Dept.	Study title	Review result	Summary minutes
1	Molecular Bioscience	CR171 "Roles of reduced lamin B1 and enhanced retrotransposon transcription in T-cell aging and inflammation" (Dr. Yoshida <i>et al.</i> )	Approved	<ol> <li>In the "Informed Consent" section, the details of consent by study subjects should be described, and the title of RP P1-11 should be stated.</li> <li>In the "Protection and anonymization of personal information" section, it should be stated that samples and information that have been anonymized and whose decoding indexes have been discarded will be used.</li> <li>The principal investigator should serve as the privacy officer.</li> <li>In the "Preservation and disposal of samples and information" section (page 18 of the RP), the method of sample disposal should be specified. Also, VII-1-1-3)-b) "Disposal is planned" (page 11 of the Application Form for Ethical Review) should be selected together with the method of disposal described.</li> <li>As for the duration of the study, state either the period starting from the date of IRB approval or the date on which the study is completed.</li> <li>The explanatory and consent documents on page 37 (Japanese version) onwards should be attached to the RP and labeled as the consent form of RP P1-11, etc.</li> <li>The date of approval by the IRB should be written in the upper right corner of the first page of the RP.</li> </ol>

\*Approved by confirming that the aforementioned revisions have duly been made.

\*To prevent the spread of COVID-19, the IRB members maintained sufficient distances from each other during the meeting.